Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;11(1):56-8.

Budesonide Extended-Release in Patients With Mild to Moderate Ulcerative Colitis

Asher Kornbluth  1
Affiliations

Budesonide Extended-Release in Patients With Mild to Moderate Ulcerative Colitis

Asher Kornbluth. Gastroenterol Hepatol (N Y). 2015 Jan.
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Brunner M, Ziegler S, Di Stefano AF, et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol. 2006;61(1):31–38. - PMC - PubMed
    1. Press AG, Hauptmann IA, Hauptmann L, et al. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 1998;12(7):673–678. - PubMed
    1. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143(5):1218–1226.e1-2. - PubMed
    1. Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from. - PMC - PubMed

LinkOut - more resources